- Home
- AMRN vs TLSI Comparison
AMRN vs TLSI Comparison
Compare AMRN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- TLSI
- Stock Information
- Founded
- AMRN 1989
- TLSI 2010
- Country
- AMRN Ireland
- TLSI United States
- Employees
- AMRN N/A
- TLSI N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- AMRN Health Care
- TLSI Health Care
- Exchange
- AMRN Nasdaq
- TLSI Nasdaq
- Market Cap
- AMRN 189.2M
- TLSI 160.4M
- IPO Year
- AMRN 1993
- TLSI N/A
- Fundamental
- Price
- AMRN $9.11
- TLSI $5.74
- Analyst Decision
- AMRN Sell
- TLSI Strong Buy
- Analyst Count
- AMRN 2
- TLSI 6
- Target Price
- AMRN $7.00
- TLSI $11.75
- AVG Volume (30 Days)
- AMRN 103.6K
- TLSI 57.4K
- Earning Date
- AMRN 04-30-2025
- TLSI 05-14-2025
- Dividend Yield
- AMRN N/A
- TLSI N/A
- EPS Growth
- AMRN N/A
- TLSI N/A
- EPS
- AMRN N/A
- TLSI N/A
- Revenue
- AMRN $228,614,000.00
- TLSI $29,431,000.00
- Revenue This Year
- AMRN N/A
- TLSI $55.08
- Revenue Next Year
- AMRN $5.18
- TLSI $50.75
- P/E Ratio
- AMRN N/A
- TLSI N/A
- Revenue Growth
- AMRN N/A
- TLSI 58.99
- 52 Week Low
- AMRN $7.00
- TLSI $3.50
- 52 Week High
- AMRN $20.60
- TLSI $10.24
- Technical
- Relative Strength Index (RSI)
- AMRN 48.45
- TLSI 59.91
- Support Level
- AMRN $8.32
- TLSI $5.23
- Resistance Level
- AMRN $10.06
- TLSI $5.66
- Average True Range (ATR)
- AMRN 0.87
- TLSI 0.34
- MACD
- AMRN 0.15
- TLSI 0.03
- Stochastic Oscillator
- AMRN 60.40
- TLSI 92.94
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.